GSK Pharma Stock - FDA clears Utebzi oral antibiotic

GSK Pharma stock is back on traders' screens after parent group GSK secured FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, underscoring the pipeline link between the Indian arm and its global parent.

Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 20:42 UTC. Details in the imprint.

GSK Pharma (INE159A01016) sits in a global spotlight today after parent company GSK secured US FDA approval for Utebzi, the first oral carbapenem antibiotic for complicated urinary tract infections in adults, according to a 6-K filing and supporting coverage. The SEC-filed 6-K highlights the Utebzi approval.

What the FDA approval covers

The US Food and Drug Administration has approved Utebzi (tebipenem pivoxil) as the first and only oral carbapenem for adults with complicated urinary tract infections, including pyelonephritis, who have limited or no alternative oral options. A detailed Investing.com report summarizes the label.

The approval is based on the phase III PIVOT-PO trial, in which oral tebipenem pivoxil showed non-inferiority to intravenous imipenem-cilastatin in around 1,700 hospitalized patients, with overall success rates of 58.5% versus 60.2%, respectively. GuruFocus highlights the pivotal trial data.

How it matters for GSK Pharma India

GSK Pharma operates as the Indian listed arm of the global GSK group, marketing and distributing prescription medicines and vaccines under license from its parent, including several global brands in respiratory, anti-infectives and vaccines portfolios.

While Utebzi is initially a US-focused launch, the approval underscores GSK’s broader anti-infectives strategy, which can feed into future in-licensing or launches in India if regulators and the parent company align on local opportunities.

The business behind the stock

GSK Pharma generates most of its revenue from therapeutic areas such as anti-infectives, respiratory, dermatology and vaccines, where it commercializes products like Augmentin, Betnovate and various pediatric and adult vaccines for the Indian market.

Where the stock trades today

The shares of GSK Pharma (INE159A01016) trade on the National Stock Exchange of India under the ticker GLAXO; a recent verified reference quote shows the stock last around INR 2,478.90 on NSE as of 12/24/2025, 14:27 IST.

Key facts on GSK Pharma stock

• Company: GlaxoSmithKline Pharmaceuticals Limited
• ISIN: INE159A01016
• WKN: 590300
• Ticker: GLAXO
• Venue: NSE
• Price (as of 12/24/2025, 14:27 IST): 2,478.90 INR
• Market cap: 38,961.70 crore INR (as of 05/26/2026)
• Sector / Industry: Health Care - Pharmaceuticals
• Index membership: Nifty indices membership not prominently cited in latest reference data
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.